@inproceedings{morschhauser:hal-04344767,
TITLE = {Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)},
AUTHOR = {Morschhauser, Franck and Patel, Krish and Bobillo, Sabela and Cordoba, Raul and Eyre, Toby A and Bishton, Mark and Houot, Roch and Zhang, Hui-Lai and Zou, Liqun and Osborne, Wendy and G{\'a}lvez-Carvajal, Laura and Thieblemont, Catherine and Yee, Donald and Knapp, Andrea and Purev, Enkhtsetseg and Li, Haocheng and Chen, Vivian and L. Banta, Karl and Sit, Jason and Bachy, Emmanuel},
URL = {https://hal.science/hal-04344767},
BOOK
TITLE = {65th ASH Annual Meeting},
ADDRESS = {San Diego, United States},
VOLUME = {142},
NUMBER = {Supplement 1},
PAGES = {605},
YEAR = {2023},
MONTH = Dec, DOI = {10.1182/blood-2023-174432},
KEYWORDS = {Lenalidomide ; Medicine ; Internal medicine ; Oncology ; Follicular lymphoma ; Phases of clinical research ; Chemotherapy ; Lymphoma ; Surgery ; Multiple myeloma},
HAL_ID = {hal-04344767},
HAL_VERSION = {v1},
}